한글목차

본 보고서는 급성 골수성 백혈병(AML)의 현재 및 향후 치료 현황을 표적치료제에 초점을 맞추어 상세하게 분석하였습니다. 미국과 유럽의 KOL(Key Opinion Leader)들의 의견을 바탕으로 베네토클락스, FLT3 억제제, IDH 억제제 등 치료제의 사용 현황과 영향력을 검증하고 있습니다. 또한, 병용요법의 역할 증가와 새로운 치료의 가능성에 초점을 맞추어 향후 5년 동안 치료 알고리즘이 어떻게 진화할 것인지에 대해 자세히 살펴봅니다. 이러한 주요 발견과 AML 치료 전략에 미치는 영향에 대한 귀중한 통찰력을 얻을 수 있습니다.

보고서 내용

• KOL들이 AML 치료에서 AbbVie/Roche의 Venclexta/Venclyxto(venetoclax)를 어떻게 사용하고 있는가?
• Venclexta/Venclyxto 병용요법에 대한 KOL의 견해
• KOL은 FLT3 억제제를 어떻게 활용하고 있으며, 어떤 약물을 선호한다고 생각하는가?
• AML에서 IDH 억제제는 어떻게 사용됩니까?
• Jazz Pharmaceuticals의 Vyxeos에 대한 전문가 의견, 표준 화학요법과 비교한 전문가 의견
• 유럽 KOL들이 Inaqovi를 사용하는 방법과 미국 시장에서의 잠재력
• f Revuforj (revumenib) 승인과 기대되는 보급에 대한 미국 KOL의 의견
• Iomab-B의 잠재력과 임상 3상 SIERRA 시험 결과에 대한 KOL의 의견은?
• 전문가들은 Zeltherva, Orca-T, iadademstat와 같은 파이프라인 의약품의 가능성을 어떻게 보고 있는가?
• 향후 5년간 AML 치료 알고리즘이 어떻게 진화할 것으로 예상하는가?

주요 브랜드

영문목차

This report provides an in-depth analysis of the current and future treatment landscape for acute myeloid leukaemia (AML), focusing on targeted therapies. Based on insights from key opinion leaders across the USA and Europe, it examines the use and impact of therapies like venetoclax, FLT3 inhibitors, and IDH inhibitors. The report highlights the increasing role of combination therapies and the potential of new treatments, providing a detailed look at how the treatment algorithm is expected to evolve over the next five years. Gain valuable insights into these major findings and their implications for AML treatment strategies.

Key Questions Answered:

• How do KOLs use AbbVie/Roche's Venclexta/Venclyxto (venetoclax) in AML treatment?
• What are KOLs' views on Venclexta/Venclyxto combination therapies?
• How do KOLs utilize FLT3 inhibitors, and which agents are preferred?
• How are IDH inhibitors used in AML according to KOLs?
• What is the expert opinion on Jazz Pharmaceuticals' Vyxeos compared to standard chemotherapy?
• How do European KOLs use Inaqovi, and what is its potential in the US market?
• What are US KOLs' opinions on the approval and expected uptake of Revuforj (revumenib)?
• What do KOLs think of Iomab-B's potential and the Phase III SIERRA trial results?
• How do experts view the potential of pipeline agents like Zeltherva, Orca-T, and iadademstat?
• How is the AML treatment algorithm expected to evolve over the next five years?

Key Brands:

Partial List of Participating Experts:

• Director, Georgia Cancer Center at Augusta University, Augusta, GA
• Professor, Translational Science and Therapeutics Division, Fred Hutch Cancer Center, WA
• Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, TX
• Professor of Haematology, Faculty of Medicine & Health Sciences at the University of Nottingham, Nottingham, UK
• Associate Professor of Haematology in the Department of Biomedicine and Prevention at the University of Rome Tor Vergata, Italy
• Professor Clinician at the Centre Hospitalier Universitaire (CHU) Bordeaux, Universite Bordeaux, Bordeaux, France

Methodology

Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.